About the Company
Forma Therapeutics is a clinical-stage biopharmaceutical company focused on the research, development and commercialization of novel therapeutics to transform the lives of patients with rare hematologic diseases and cancers. Its R&D engine combines deep biology insight, chemistry expertise and clinical development capabilities to create drug candidates with differentiated mechanisms of action focused on indications with high unmet need. Its work has generated a broad proprietary portfolio of programs with the potential to provide profound patient benefit.
Fundamental Data and Insider Transactions (Quarterly data) Full Screen
Loading the fundamentals chart...
Latest $FMTX News
Forma Therapeutics
This page shows the latest Forma Therapeutics news and features for those working in and with pharma, biotech and healthcare. The acquisition includes a pipeline of haemoglobinopathies including ...
Forma Therapeutics to Present at 11th Annual SVB Leerink Healthcare Conference
Forma Therapeutics Holdings, Inc. (Nasdaq: FMTX), a clinical-stage biopharmaceutical company focused on sickle cell disease, prostate cancer and other rare hematologic diseases and cancers ...
CERo Therapeutics Holdings Inc
We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...
Steven Edward Hall's Net Worth
Who is Steven Edward Hall? Steven Edward Hall has an estimated net worth of $114 Million. This is based on reported shares across multiple companies, which include Protagonist Therapeutics, Inc ...
Arcturus Therapeutics Holdings, Inc.
Arcturus Therapeutics Holdings, Inc. operates as a late-stage clinical mRNA medicines and vaccine company, which engages in the development of infectious disease vaccines and significant ...
Wellington Biomedical Innovation Master Investors (Cayman) I L.P.'s Net Worth
Who is Wellington Biomedical Innovation Master Investors (Cayman) I L.P.? Wellington Biomedical Innovation Master Investors (Cayman) I L.P. has an estimated net worth of $183 Million. This is ...
Cerevel Therapeutics Holdings Inc
Cerevel Therapeutics Holdings, Inc. engages in the discovery and development of new therapies for neuroscience diseases. The firm's portfolio focuses on diseases such as schizophrenia, epilepsy ...
Rani Therapeutics Holdings, Inc. (RANI)
Rani Therapeutics Holdings, Inc. (NASDAQ:RANI) Q4 2023 Earnings Call Transcript March 20, 2024 Rani Therapeutics Holdings, Inc. beats earnings expectations. Reported EPS is $-0.27, expectations ...
Rani Therapeutics Shares Exciting Clinical Trial Results
Rani Therapeutics Holdings, Inc. has released promising topline results from its RT-111 Phase 1 clinical trial, capturing the ...
What Makes Rani Therapeutics Holdings, Inc. (RANI) a New Buy Stock
Earnings Estimate Revisions for Rani Therapeutics Holdings, Inc. This company is expected to earn -$1.39 per share for the fiscal year ending December 2023, which represents a year-over-year ...
Arcturus Therapeutics Holdings, Inc.
Arcturus Therapeutics Holdings, Inc. operates as a late-stage clinical mRNA medicines and vaccine company, which engages in the development of infectious disease vaccines and significant ...
Rani Therapeutics Holdings, Inc. (RANI)
Overall score is calculated based on proprietary scores based on sector averages in key company indicators: fair value, dividends, innovation, hiring, and insider sentiment. Note: if you don't see ...
Loading the latest forecasts...